PDCD1 and head and neck squamous cell carcinoma: The introduction of PD-1/PD-L1 inhibitors for the treatment of patients with relapsed and/or metastatic HNSCC raises the important issue of the reliability and reproducibility of the theranostic evaluation of PD-L1 expression.